These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1934525)
21. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425 [TBL] [Abstract][Full Text] [Related]
22. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Balasch J; Miró F; Burzaco I; Casamitjana R; Civico S; Ballescá JL; Puerto B; Vanrell JA Hum Reprod; 1995 Jul; 10(7):1678-83. PubMed ID: 8582960 [TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations in fluid from human stimulated follicles. Oosterhuis GJ; Vermes I; Lambalk CB; Michgelsen HW; Schoemaker J Hum Reprod; 1998 Feb; 13(2):285-9. PubMed ID: 9557823 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of low dose purified FSH in ovulation induction following pituitary desensitization in polycystic ovarian syndrome. Buckler HM; Critchley HO; Cantrill JA; Shalet SM; Anderson DC; Robertson WR Clin Endocrinol (Oxf); 1993 Feb; 38(2):209-17. PubMed ID: 8435902 [TBL] [Abstract][Full Text] [Related]
26. A comparative study of single-dose growth hormone therapy as an adjuvant to gonadotrophin treatment for ovulation induction. Homburg R; West C; Torresani T; Jacobs HS Clin Endocrinol (Oxf); 1990 Jun; 32(6):781-5. PubMed ID: 2200622 [TBL] [Abstract][Full Text] [Related]
27. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119 [TBL] [Abstract][Full Text] [Related]
28. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT. Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971 [TBL] [Abstract][Full Text] [Related]
29. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone. Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235 [TBL] [Abstract][Full Text] [Related]
30. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. van der Meer S; Gerris J; Joostens M; Tas B Hum Reprod; 1993 Oct; 8(10):1628-31. PubMed ID: 8300818 [TBL] [Abstract][Full Text] [Related]
31. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon). Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080 [TBL] [Abstract][Full Text] [Related]
32. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction. Yding Andersen C; Westergaard LG; Figenschau Y; Bertheussen K; Forsdahl F Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072 [TBL] [Abstract][Full Text] [Related]
33. A study of the effects of bromocriptine on serum prolactin, follicle stimulating hormone and luteinizing hormone and on ovarian responsiveness to exogenous gonadotrophins in anovulatory women. Pepperell RJ; Evans JH; Brown JB; Bright MI; Smith MA; Burger HG; Healy D Br J Obstet Gynaecol; 1977 Jun; 84(6):456-63. PubMed ID: 578115 [TBL] [Abstract][Full Text] [Related]
34. In vitro fertilisation. A review of drug therapy and clinical management. Jennings JC; Moreland K; Peterson CM Drugs; 1996 Sep; 52(3):313-43. PubMed ID: 8875126 [TBL] [Abstract][Full Text] [Related]
35. Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. van Dessel HJ; Schoot BC; Schipper I; Dahl KD; Fauser BC Hum Reprod; 1996 Mar; 11(3):478-85. PubMed ID: 8671250 [TBL] [Abstract][Full Text] [Related]
36. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Homburg R; Howles CM Hum Reprod Update; 1999; 5(5):493-9. PubMed ID: 10582786 [TBL] [Abstract][Full Text] [Related]
37. Relationship between the threshold of ovarian sensitivity to human menopausal gonadotrophin stimulation and in-vitro fertilization treatment outcome. Shulman A; Ghetler Y; Fejgin M; Kaneti H; Weinstein S; Beyth Y; Ben-Nun I Hum Reprod; 1995 Dec; 10(12):3198-201. PubMed ID: 8822443 [TBL] [Abstract][Full Text] [Related]
38. Ovarian stimulation in an infertile patient with growth hormone-deficient Oliver-Mcfarlane syndrome. Shaker AG; Fleming R; Jamieson ME; Yates RW; Coutts JR Hum Reprod; 1994 Nov; 9(11):1997-8. PubMed ID: 7868663 [TBL] [Abstract][Full Text] [Related]
39. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins. Dawood MY; Jarrett JC; Choe JK Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337 [TBL] [Abstract][Full Text] [Related]